Baxter International (NYSE:BAX) initiated with Sector Weight rating at KeyBanc.
Kadmon Holdings (NYSE:KDMN) initiated with Outperform rating and $6 (264% upside) price target at Oppenheimer.
Matinas BioPharma Holdings (NYSEMKT:MTNB) initiated with Buy rating and $4 (398% upside) pride target at H.C. Wainwright.
Acasti Pharma (NASDAQ:ACST) initiated with Buy rating and $6 (471% upside) price target at H.C. Wainwright. Shares up 7% premarket.
Rubius Therapeutics (NASDAQ:RUBY) initiated with Buy rating and $40 (174% upside) price target at H.C. Wainwright.
Denali Therapeutics (NASDAQ:DNLI) initiated with Buy rating and $28 (39% upside) price target at H.C. Wainwright.
Eiger BioPharmaceuticals (NASDAQ:EIGR) initiated with Buy rating and $22 (105% upside) price target at Citigroup.
Titan Pharmaceuticals (NASDAQ:TTNP) initiated with Buy rating and $4 (178% upside) price target at Maxim Group.
AbbVie (NYSE:ABBV) upgraded to Outperform with an $88 (40% upside) price target at SVB Leerink. Shares up 1% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.